AIM: Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth factor receptor (EGFR) tyrosine kinase. The aim of this study was to investigate the relationship between erlotinib plasma concentrations and phosphorylated EGFR (pEGFR) levels, as well as the relationship between pEGFR levels and tumor growth inhibition in a human non-small-cell lung cancer xenograft mouse model. METHODS: Female BALB/c nude mice were implanted with the human NSCLC cell line SPC-A-1. The animals were given via gavage a single dose of erlotinib (4, 12.5, or 50 mg/kg). Pharmacokinetics of erlotinib was determined using LC-MS/MS. Tumor volume and pEGFR levels in tumor tissues were measured at different time points after erlotinib administration. The levels of pEGFR in tumor tissues was detected using Western blotting and ELISA assays. RESULTS: The pharmacokinetics of erlotinib was described by a two-compartment model with first order extravascular absorption kinetics. There was a time delay of approximately 2 h between erlotinib plasma concentrations and pEGFR degradation. The time course of pEGFR degradation was reasonably fit by the indirect response model with a calculated IC50 value of 1.80 μg/mL. The relationship between pEGFR levels and tumor volume was characterized by the integrated model with a Kbio value of 0.507 cm(3)/week, which described the impact of pEGFR degradation on tumor growth. CONCLUSION: The pharmacokinetic/pharmacodynamic properties of erlotinib in a human tumor xenograft model were described by the indirect response model and integrated model, which will be helpful in understanding the detailed processes of erlotinib activity and determining an appropriate dosing regimen in clinical studies.
AIM: Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth factor receptor (EGFR) tyrosine kinase. The aim of this study was to investigate the relationship between erlotinib plasma concentrations and phosphorylated EGFR (pEGFR) levels, as well as the relationship between pEGFR levels and tumor growth inhibition in a human non-small-cell lung cancer xenograft mouse model. METHODS: Female BALB/c nude mice were implanted with the humanNSCLC cell line SPC-A-1. The animals were given via gavage a single dose of erlotinib (4, 12.5, or 50 mg/kg). Pharmacokinetics of erlotinib was determined using LC-MS/MS. Tumor volume and pEGFR levels in tumor tissues were measured at different time points after erlotinib administration. The levels of pEGFR in tumor tissues was detected using Western blotting and ELISA assays. RESULTS: The pharmacokinetics of erlotinib was described by a two-compartment model with first order extravascular absorption kinetics. There was a time delay of approximately 2 h between erlotinib plasma concentrations and pEGFR degradation. The time course of pEGFR degradation was reasonably fit by the indirect response model with a calculated IC50 value of 1.80 μg/mL. The relationship between pEGFR levels and tumor volume was characterized by the integrated model with a Kbio value of 0.507 cm(3)/week, which described the impact of pEGFR degradation on tumor growth. CONCLUSION: The pharmacokinetic/pharmacodynamic properties of erlotinib in a humantumor xenograft model were described by the indirect response model and integrated model, which will be helpful in understanding the detailed processes of erlotinib activity and determining an appropriate dosing regimen in clinical studies.
Authors: Feng R Luo; Zheng Yang; Amy Camuso; Richard Smykla; Kelly McGlinchey; Krista Fager; Christine Flefleh; Stephen Castaneda; Ivan Inigo; David Kan; Mei-Li Wen; Robert Kramer; Anne Blackwood-Chirchir; Francis Y Lee Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Malcolm Ranson; Lisa A Hammond; David Ferry; Mark Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steve Averbuch; Judy Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: Feng R Luo; Zheng Yang; Huijin Dong; Amy Camuso; Kelly McGlinchey; Krista Fager; Christine Flefleh; David Kan; Ivan Inigo; Stephen Castaneda; Tai W Wong; Robert A Kramer; Robert Wild; Francis Y Lee Journal: Clin Cancer Res Date: 2005-08-01 Impact factor: 12.531
Authors: Lucy Lee; Huifeng Niu; Ruediger Rueger; Yuriko Igawa; Jonathan Deutsch; Nobuya Ishii; Song Mu; Yuuichiro Sakamoto; Rachel Busse-Reid; Claude Gimmi; Petra Goelzer; Stefanie De Schepper; Yashushi Yoshimura; Joanne Barrett; Yuji Ishikawa; Georges Weissgerber; Richard Peck Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Antoinette R Tan; Xiaowei Yang; Stephen M Hewitt; Arlene Berman; Erin R Lepper; Alex Sparreboom; Allyson L Parr; William D Figg; Catherine Chow; Seth M Steinberg; Stephen L Bacharach; Millie Whatley; Jorge A Carrasquillo; Jaime S Brahim; Seth A Ettenberg; Stan Lipkowitz; Sandra M Swain Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Roberto Fernández; Jone Garate; Sergio Lage; Silvia Terés; Mónica Higuera; Joan Bestard-Escalas; Daniel H López; Francisca Guardiola-Serrano; Pablo V Escribá; Gwendolyn Barceló-Coblijn; José A Fernández Journal: J Am Soc Mass Spectrom Date: 2015-09-25 Impact factor: 3.109
Authors: Roberto Fernández; Sergio Lage; Beatriz Abad-García; Gwendolyn Barceló-Coblijn; Silvia Terés; Daniel H López; Francisca Guardiola-Serrano; M Laura Martín; Pablo V Escribá; José A Fernández Journal: J Am Soc Mass Spectrom Date: 2014-04-24 Impact factor: 3.109